Dogwood Therapeutics, Inc. DWTX
Set alert
1.28 USD +0.05 +4.07%
At close · Oct 30
1.33 +0.05 +3.88%
After hours · Oct 30, 7:48 PM ET
1.28 Day range 1.36
1.11 52-week range 6.82
- YTD
- -69.23%
- 1 year
- -80.75%
- Open
- 1.30
- Prev close
- 1.23
- Mkt cap
- 43.51M
- Vol
- 62.22K
- Avg vol
- 69.79K
- EPS
- 2.20
- P/E
- 0.58
- Div yield
- 0.00%
More statistics
- Low
- 1.28
- High
- 1.36
- Forward P/E
- -0.43
- Beta
- 0.00
- Short ratio
- 0.42
- Inst. own
- 3.24%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 3.32
- 200-d avg
- 6.07
- 1y target
- 13.83
5D chart
Signals (22)
| Name | Time | Ago |
|---|---|---|
| SMA: Bullish | Oct 28, 3:10 PM | 3 days ago |
| SMA: Bearish | Oct 28, 3:00 PM | 3 days ago |
| SMA: Bullish | Oct 28, 2:50 PM | 3 days ago |
| SMA: Bearish | Oct 28, 1:30 PM | 3 days ago |
| MACD: Sell Signal | Oct 28, 1:30 PM | 3 days ago |
| RSI: Overbought | Oct 28, 12:30 PM | 3 days ago |
| RSI: Overbought | Oct 28, 9:55 AM | 3 days ago |
| SMA: Bullish | Oct 27, 3:35 PM | 4 days ago |
| SMA: Bullish | Oct 27, 3:35 PM | 4 days ago |
| SMA: Bearish | Oct 27, 11:30 AM | 4 days ago |
| SMA: Bullish | Oct 27, 9:55 AM | 4 days ago |
| MACD: Buy Signal | Oct 27, 9:55 AM | 4 days ago |
| SMA: Bullish | Oct 27, 9:30 AM | 4 days ago |
| MACD: Sell Signal | Oct 26, 2:40 PM | 5 days ago |
| MACD: Buy Signal | Oct 26, 1:40 PM | 5 days ago |
| SMA: Bearish | Oct 23, 3:25 PM | 1 week ago |
| SMA: Bullish | Oct 23, 3:20 PM | 1 week ago |
| MACD: Sell Signal | Oct 23, 3:10 PM | 1 week ago |
| SMA: Bearish | Oct 23, 3:05 PM | 1 week ago |
| SMA: Bearish | Oct 23, 3:05 PM | 1 week ago |
| SMA: Bullish | Oct 23, 9:30 AM | 1 week ago |
| SMA: Bearish | Oct 22, 12:30 PM | 1 week ago |
Key statistics
- Market cap
- 3.62M
- Enterprise value
- 0
- Trailing P/E
- 0.00
- Forward P/E
- -0.43
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.55
- EPS (TTM)
- -6.32
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- 0
- Total cash
- 0
- Total debt
- 0
- Return on equity
- 0.00%
- Shares outstanding
- 1.33M
- Short % of float
- 2.56%
- 50-day average
- 3.32
- 200-day average
- 6.07
Analyst view
Consensus: none
Price target (mean) 13.83 +980.7% upside
Now 1.28
- Target (low)
- 5.00
- Target (mean)
- 13.83
- Target (high)
- 25.00
Ratings (0m) 2 1 buy · 1 hold · 0 sell
- Strong buy1
- Buy0
- Hold1
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
DWTX Revenue — quarterly 0
DWTX Net income — quarterly -11.53M
DWTX EPS — quarterly -0.34
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 7, 2024 | Sep 1, 2024 | -1.33 | -2.05 | -0.72 | -54.14% |
About Dogwood Therapeutics, Inc.
Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It also develops IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly known as Virios Therapeutics, Inc. and changed its name to Dogwood Therapeutics, Inc. in October 2024. The company was founded in 2012 and is headquartered in Alpharetta, Georgia.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- dwtx.com
News
- Dogwood Therapeutics Enters Into Securities Subscription Agreement For $5 Investment From CK Life Sciences’ Subsidiary
- Dogwood to Participate in the 2026 Maxim Growth Summit
- Dogwood Announces Completion of Enrollment in Ongoing Halneuron® Phase 2b Trial
- 12 Health Care Stocks Moving In Friday's After-Market Session
- 12 Health Care Stocks Moving In Friday's Pre-Market Session
- Dogwood Therapeutics, Inc. (DWTX) Discusses Halneuron and Pipeline Advances for Chemotherapy-Induced Neuropathic Pain Transcript
- Dogwood Therapeutics Nears Phase 2b Readout for Halneuron Neuropathic Pain Treatment
- 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- Dogwood to Host Virtual KOL Event to Discuss Halneuron® for the Treatment of Chemotherapy Induced Neuropathic Pain on September 1, 2026
- Dogwood Therapeutics Q2 EPS $(0.34) Misses $(0.14) Estimate
Your note
Sign in to keep a note on DWTX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| DUNCAN GREGORY SCOTT | Chief Executive Officer | Purchase | Aug 16, 2023 | 57,461 |
| PRIDGEN WILLIAM L | Director | Purchase | Aug 20, 2023 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Geode Capital Management, LLC | 1.39% | 18,460 | 50.21K | Sep 29, 2024 |
| Vanguard Group Inc | 1.25% | 16,711 | 45.45K | Sep 29, 2024 |
| UBS Group AG | 1.12% | 14,885 | 40.49K | Sep 29, 2024 |
| HRT Financial LP | 0.49% | 6,526 | 17.75K | Sep 29, 2024 |
| State Street Corporation | 0.32% | 4,226 | 11.49K | Sep 29, 2024 |
| Two Sigma Securities, LLC | 0.32% | 4,271 | 11.62K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Extended Market Index Fund | 1.25% | 16,711 | 45.45K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.45% | 5,942 | 16.16K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.17% | 2,294 | 6.24K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.13% | 1,750 | 4.76K | Oct 30, 2024 |
| Fidelity NASDAQ Composite Index Fund | 0.07% | 880 | 2.39K | Oct 30, 2024 |